SCHEMBL704493

SCHEMBL704493

CC12CCCN1C(=O)N(c1ccccc1C(F)(F)F)C2

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
AR P10275 2/20 0.42
PGR P06401 1/20 0.42
HTR1A P08908 1/20 0.41
CYP3A4 P08684 1/20 0.38
HSD11B1 P28845 1/20 0.38
TDP1 Q9NUW8 5/20 0.38
NOTUM Q6P988 1/20 0.37
AKR1C3 P42330 1/20 0.36
L3MBTL1 Q9Y468 5/20 0.36
RBP4 P02753 1/20 0.35
TTR P02766 1/20 0.35
P2RX7 Q99572 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
KDM4E B2RXH2 1/20 0.35
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL704636 0.80 HSD11B1 (0.46) HTR1AHSD11B1L3MBTL1MAPT
SCHEMBL16915007 0.69 SCN9A (0.46) HTR1ACYP3A4HSD11B1TDP1NOTUM
SCHEMBL76732 0.68 L3MBTL1 (0.43) HTR1ACYP3A4HSD11B1TDP1NOTUM
SCHEMBL9223129 0.67 KMT2A (0.43) HTR1AHSD11B1TDP1AKR1C3L3MBTL1
SCHEMBL292701 0.67 AR (0.44) ARCYP3A4HSD11B1TDP1NOTUM
SCHEMBL19962678 0.67 MEN1 (0.45) HTR1ACYP3A4HSD11B1TDP1NOTUM
SCHEMBL28133419 0.66 P2RY1 (0.46) CYP3A4HSD11B1TDP1NOTUML3MBTL1
SCHEMBL30483507 0.66 MEN1 (0.41) HTR1ATDP1NOTUMAKR1C3L3MBTL1
SCHEMBL11114358 0.66 TDP1 (0.45) TDP1L3MBTL1RBP4MEN1KMT2A
SCHEMBL8728249 0.65 MAPT (0.46) CYP3A4TDP1L3MBTL1P2RX7MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2280970-B1 IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS HOFFMANN LA ROCHE (CH) 2014-01-08 EP claimed
US-8124636-B2 Imidazolidinone derivatives as 11B-HSD1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2012-02-28 US claimed
EP-2280970-A1 IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS F. Hoffmann-La Roche AG (CH) 2011-02-09 EP claimed
WO-2009132986-A1 IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2009-11-05 WO claimed
US-20090275573-A1 Imidazolidinone Derivatives as 11B-HSD1 Inhibitors HOFFMANN-LA ROCHE, INC. 2009-11-05 US claimed
EP-2280970-B1 IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS HOFFMANN LA ROCHE (CH) 2014-01-08 EP disclosed
US-8124636-B2 Imidazolidinone derivatives as 11B-HSD1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2012-02-28 US disclosed
EP-2280970-A1 IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS F. Hoffmann-La Roche AG (CH) 2011-02-09 EP disclosed
WO-2009132986-A1 IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2009-11-05 WO disclosed
US-20090275573-A1 Imidazolidinone Derivatives as 11B-HSD1 Inhibitors HOFFMANN-LA ROCHE, INC. 2009-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275573-A1 Imidazolidinone Derivatives as 11B-HSD1 Inhibitors HSD11B1, HSD17B1, HSD17B11 AR 103/4885PGR 262/4885HTR1A 1037/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.